CytomX Therapeutics (CTMX) Tops Q1 EPS by 25c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of $0.17, $0.25 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $41.46 million versus the consensus estimate of $19.92 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• Pfizer lung cancer drug misses survival goal in Phase 3 trial